Accessibility Menu

Klotho Neurosciences(NASDAQ) WENA

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2022)-98%
5 YearN/A
1 Year-80%
1 Month-19%
N/A
Klotho Neurosciences last closing stock price
MetricPriceDate
Last closeUSD 0.192026-07-31
Klotho Neurosciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.62%USD 0.192026-07-24
1 month-19.25%USD 0.242026-07-01
3 month-62.41%USD 0.522026-05-01
Year to date-32.94%USD 0.292025-12-31
1 year-79.89%USD 0.962025-07-31
3 year-98.17%USD 10.612023-08-01
Since inception-98.02%USD 9.892022-04-29

Klotho Neurosciences Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$195.80K

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

N/A

WENA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Klotho Neurosciences

Klotho Neurosciences, Inc. is a biopharmaceutical company dedicated to developing innovative medical treatments for conditions such as cancer, cardiovascular diseases, and neurodegenerative disorders. The company is particularly focused on gene therapy, with key assets including AMI-101 for Alzheimer's disease and AMI-202 for amyotrophic lateral sclerosis.

Products and Services
  • Gene therapy for Alzheimer's disease (AMI-101)
  • Gene therapy for amyotrophic lateral sclerosis (AMI-202)
  • Research and development in neurodegenerative disorders
Growth Outlook
  • Significant market potential in neurodegenerative disease treatments
  • Recent name change reflects strategic focus on neuroscience
  • Strong pipeline with multiple gene therapy candidates in development
Financial Highlights
  • Quarterly net income of -$13.86 million as of March 31, 2026
  • Cash and cash equivalents of $10 million as of March 31, 2026
  • Current ratio of 19.74 indicates strong liquidity position
Klotho Neurosciences, Inc. operates in a promising sector with a focus on addressing critical health challenges. The company's innovative gene therapy products aim to tackle some of the most pressing medical issues, particularly in neurodegenerative diseases. The recent financial data indicates a robust liquidity position, which is essential for ongoing research and development efforts. The significant market potential for treatments in this area, combined with a strong pipeline, positions Klotho Neurosciences as a noteworthy player in the biotechnology industry.
AI Generated • Jul 22, 2026

Industry

Biotechnology

Sector

Health Care

Employees

5

CEO

Joseph Sinkule, PharmD

Website

www.klothoneuro.com

Headquarters

Omaha, NE 68144, US

WENA Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

2.16%

Return on Capital

-10.15%

Return on Assets

6.92%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$1.36M

EBITDA

-$1.36M

Operating Cash Flow

-$1.18M

Capital Expenditure

-$123.50K

Free Cash Flow

-$1.30M

Cash & ST Invst.

$845.34K

Total Debt

$3.93M

Klotho Neurosciences Performance Analysis

Klotho Neurosciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Klotho Neurosciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32023-09-30N/A
Q42023-12-31N/A
Q12024-03-31N/A
Q22024-06-30N/A
Klotho Neurosciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 0.08N/A
20232023-12-31USD -0.05N/A
20242024-12-31USD -0.32582.7%
20252025-12-31USD -0.22-31.9%
Klotho Neurosciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32023-09-30289.7%
Q42023-12-31-47.9%
Q12024-03-31-239.0%
Q22024-06-30-25.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2024YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

1

N/A

Net Income

-$451.64K

-194.1%

EBITDA

-$395.61K

-62.0%

Quarterly Fundamentals

Name
Q2 2024YOY CHG

Total Cash

$845.34K

+583.3%

Total Debt

$3.93M

+351.8%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$3.90M

N/A

Short Term Debt

$31.00K

-97.7%

Return on Assets

6.92%

N/A

Return on Invested Capital

-7.59%

N/A

Free Cash Flow

-$548.36K

-6.8%

Operating Cash Flow

-$424.86K

+17.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ATONAlphaTON Capital Corp.
$0.29+22.68%
IMNNImunon, Inc.
$1.59-0.63%
CYADCelyad Oncology S.A.
$0.47-12.96%
PIRSPieris Pharmaceuticals, Inc.
$13.60-15.58%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About WENA

What is the current price of Klotho Neurosciences?

Klotho Neurosciences is trading at N/A per share.

What is the 52-week range for Klotho Neurosciences?

Over the past 52 weeks, Klotho Neurosciences has traded between N/A and N/A.

How much debt does Klotho Neurosciences have?

As of the most recent reporting period, Klotho Neurosciences reported total debt of $294.54K.

How much cash does Klotho Neurosciences have on hand?

Klotho Neurosciences reported $10.00M in cash and cash equivalents in its most recent financial results.

What is Klotho Neurosciences’s dividend yield?

Klotho Neurosciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services